Related Experiment Video
Updated: Feb 11, 2026
Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
Published on: March 2, 2011
The Drug Reimbursement Decision-Making System in Iran
Amir Ansaripour1, Carin A Uyl-de Groot2, Adri Steenhoek2
1Department of Health, Social Security Organization, Tehran, Iran; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Background:
Previous studies of health policies in Iran have not focused exclusively on the drug reimbursement process.
Objective:
The aim of this study was to describe the entire drug reimbursement process and the stakeholders, and discuss issues faced by policymakers.
Methods:
Review of documents describing the administrative rules and directives of stakeholders, supplemented by published statistics and interviews with experts and policymakers.
Results:
Iran has a systematic process for the assessment, appraisal, and judgment of drug reimbursements. The two most important organizations in this process are the Food and Drug Organization, which considers clinical effectiveness, safety, and economic issues, and the Supreme Council of Health Insurance, which considers various criteria, including budget impact and cost-effectiveness. Ultimately, the Iranian Cabinet approves a drug and recommends its use to all health insurance organizations. Reimbursed drugs account for about 53.5% of all available drugs and 77.3% of drug expenditures. Despite its strengths, the system faces various issues, including conflicting stakeholder aims, lengthy decision-making duration, limited access to decision-making details, and rigidity in the assessment process.
Conclusions:
The Iranian drug reimbursement system uses decision-making criteria and a structured approach similar to those in other countries. Important shortcomings in the system include out-of-pocket contributions due to lengthy decision making, lack of transparency, and conflicting interests among stakeholders. Iranian policymakers should consider a number of ways to remedy these problems, such as case studies of individual drugs and closer examination of experiences in other countries.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
05:35Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
Published on: January 19, 2024
Related Concept Videos
01:20Decision Making
Automatic decision-making is fast, intuitive, and relies on gut feelings...
01:09Decision Making: P-value Method
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can...
01:14Decision Making: Traditional Method
First, a specific claim about the population parameter is decided based on the research question and is stated in a simple form. Further, an opposing statement to this claim is also stated. These statements can act as null and alternative hypotheses, out of which a null hypothesis would be a...
01:25Pharmacokinetics: Drug–Drug Interactions
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
01:26FDA Approved Drugs: Changes to Approved Drugs